Marttila R J, Rinne U K
Acta Neurol Scand. 1979 Mar;59(2-3):80-7. doi: 10.1111/j.1600-0404.1979.tb02914.x.
Recent studies suggest that levodopa treatment reduces the excess mortality due to Parkinson's disease, found to be three times that expected in the general population. This will affect the equilibrium state of the epidemiology of Parkinson's disease. The predicted increase in prevalence of Parkinson's disease was calculated according to two mortality patterns, one the same as expected in the general population and the other 1.5 times that expected; the proportional increase in prevalence is 1.8 and 1.4, respectively. The predicted increase in the duration of the disease if 6.3 or 3.2 years. As a consequence, there will be an increase of patients with long-term levodopa treatment difficulties, and with Parkinson's disease symptoms not treatable with levodopa, e.g. dementia. This seriously warrants the research of new approaches in the treatment of Parkinson's disease.
近期研究表明,左旋多巴治疗可降低帕金森病导致的过高死亡率,该死亡率是普通人群预期死亡率的三倍。这将影响帕金森病流行病学的平衡状态。根据两种死亡率模式计算了帕金森病患病率的预测增长情况,一种与普通人群预期相同,另一种是预期的1.5倍;患病率的比例增长分别为1.8和1.4。疾病持续时间的预测增加分别为6.3年或3.2年。因此,长期接受左旋多巴治疗存在困难以及患有左旋多巴无法治疗的帕金森病症状(如痴呆)的患者将会增加。这严重促使人们对帕金森病治疗的新方法进行研究。